A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Crinetics Pharmaceuticals, Inc.
CRNX
$7.9B
Mkt Cap
$83.73
+0.10%
Crinetics Pharmaceuticals, Inc. (CRNX) has a 5-year average return on invested capital (ROIC) of -43.2%. This is below average and may indicate limited pricing power.
Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of $8.8B. It is classified as a mid-cap stock.
Crinetics Pharmaceuticals, Inc. (CRNX) does not currently pay a regular dividend.
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Crinetics Pharmaceuticals, Inc. (CRNX) generated $-384 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Crinetics Pharmaceuticals, Inc. (CRNX) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Crinetics Pharmaceuticals, Inc. (CRNX) reported earnings per share (EPS) of $-4.95 in its most recent fiscal year.
Business Overview We are a pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. We are focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting GPCRs with small molecules that have specifically tailored pharmacology and properties. Our lead product, PALSONIFY (paltusotine), is the first once-daily, oral treatment approved by the FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for CS associated with NETs. Our deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2 expressing NETs and other SST2 expressing solid tumors.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 18M | - | - | - | - | - |
| Net Income | -496M | -465M | -298M | -215M | -164M | -108M |
| EPS | $-5.10 | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
| Free Cash Flow | -420M | -384M | -234M | -173M | -117M | -89M |
| ROIC | -30.8% | -40.2% | -32.0% | -50.2% | -50.6% | -43.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.05 | 0.04 | 0.18 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -546M | -517M | -339M | -223M | -168M | -108M |
| Operating Margin | -3020.3% | - | - | - | - | - |
| ROE | -38.8% | -40.2% | -32.0% | -50.2% | -50.6% | -43.0% |
| Shares Outstanding | 105M | 94M | 81M | 58M | 52M | 38M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 18M |
| Gross Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 5.1M | 9.2M | 24M | 42M | 57M | 84M | 130M | 169M | 240M | 332M | 356M |
| SG&A | 1.5M | 1.9M | 6.7M | 14M | 18M | 25M | -42M | 58M | 100M | 191M | 207M |
| EBIT | -6.0M | -9.1M | -29M | -54M | -75M | -108M | -168M | -223M | -339M | -517M | -546M |
| Op. Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3020.3% |
| Net Income | -6.0M | -9.2M | -27M | -50M | -74M | -108M | -164M | -215M | -298M | -465M | -496M |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2747.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K | -51K | -50K | -50K |
| Returns on Capital | |||||||||||
| ROIC | N/M | -58.5% | -37.3% | -36.4% | -51.6% | -43.0% | -50.6% | -50.2% | -32.0% | -40.2% | -30.8% |
| ROE | 180.6% | 86.3% | -37.3% | -36.4% | -51.6% | -43.0% | -50.6% | -50.2% | -32.0% | -40.2% | -38.8% |
| ROA | -5188.8% | -116.5% | -29.0% | -33.4% | -47.0% | -40.3% | -46.6% | -43.4% | -28.8% | -36.3% | -35.4% |
| Cash Flow | |||||||||||
| Op. Cash Flow | -5.5M | -9.5M | -19M | -46M | -62M | -89M | -115M | -169M | -230M | -378M | -414M |
| Free Cash Flow | -5.7M | -9.8M | -21M | -47M | -62M | -89M | -117M | -173M | -234M | -384M | -420M |
| Owner Earnings | -5.8M | -10M | -23M | -54M | -75M | -107M | -144M | -211M | -302M | -473M | -519M |
| CapEx | 190K | 304K | 1.1M | 492K | 186K | 436K | 1.7M | 4.7M | 3.8M | 5.8M | 5.3M |
| Maint. CapEx | 92K | 304K | 741K | 1.6M | 2.6M | 922K | 983K | 1.1M | 2.8M | 3.9M | 4.3M |
| Growth CapEx | 98K | 0 | 318K | 0 | 0 | 0 | 673K | 3.6M | 1.0M | 1.9M | 995K |
| D&A | 92K | 304K | 741K | 1.6M | 2.6M | 922K | 983K | 1.1M | 2.8M | 3.9M | 4.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 270K | 271K | 2.3M | 6.3M | 10M | 17M | 28M | 41M | 69M | 91M | 100M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | -12M | -14M | N/A | -113M | -166M | -330M | -331M | N/A | -1.3B | -979M | -1.3B |
| Cash & Equiv. | 12M | 14M | 45M | 40M | 93M | 201M | 33M | 55M | 265M | 102M | 1.3B |
| Long-Term Debt | 48K | 212K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.01 | -0.01 | 0.07 | 0.05 | 0.03 | 0.01 | 0.01 | 0.18 | 0.04 | 0.05 | 0.00 |
| Interest Coverage | -549.5 | -1140.9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -6.2M | -15M | 160M | 117M | 169M | 332M | 316M | 539M | 1.3B | 992M | 1.3B |
| Total Assets | 116K | 16M | 171M | 130M | 183M | 351M | 352M | 635M | 1.4B | 1.1B | 1.4B |
| Total Liabilities | 6.3M | 920K | 11M | 13M | 15M | 19M | 36M | 96M | 110M | 134M | 121M |
| Intangibles | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -16M | -43M | -94M | -168M | -275M | -439M | -654M | -952M | -1.4B | -1.5B |
| Working Capital | N/A | 14M | 159M | 115M | 167M | 329M | 317M | 530M | 1.3B | 963M | 1.3B |
| Current Assets | N/A | 15M | 167M | 123M | 177M | 345M | 345M | 574M | 1.4B | 1.0B | 1.3B |
| Current Liabilities | N/A | 897K | 7.9M | 8.3M | 10M | 16M | 28M | 44M | 60M | 85M | 71M |
| Per Share Data | |||||||||||
| EPS | -5.96 | -6.68 | -1,126.93 | -2.09 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 | -4.95 | -5.10 |
| Owner EPS | -5.77 | -7.33 | -935.95 | -2.25 | -2.46 | -2.78 | -2.78 | -3.62 | -3.74 | -5.03 | -4.93 |
| Book Value | -6.14 | -10.96 | 6,659.12 | 4.86 | 5.54 | 8.63 | 6.08 | 9.27 | 16.38 | 10.55 | 12.16 |
| Cash Flow/Share | -5.41 | -6.91 | -808.74 | -1.92 | -2.03 | -2.30 | -2.21 | -2.90 | -2.85 | -4.02 | -4.67 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.0M | 1.4M | 0.0M | 24.1M | 30.5M | 38.4M | 52.0M | 58.1M | 80.9M | 94.0M | 105.3M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -16.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.7 | 4.9 | N/A | 3.1 | 2.8 | 3.9 | 3.2 | 4.5 | 6.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 488.0 |
| FCF Yield | N/A | N/A | -2.7% | -8.1% | -0.0% | -8.6% | -13.0% | -8.3% | -5.6% | -8.5% | -4.8% |
| Market Cap | 0 | N/A | 750M | 579M | 637.4B | 1.0B | 896M | 2.1B | 4.2B | 4.5B | 8.8B |
| Avg. Price | 0.00 | N/A | 28.83 | 21.96 | 16.76 | 19.52 | 19.69 | 22.35 | 48.25 | 36.19 | 83.73 |
| Year-End Price | 0.00 | N/A | 30.51 | 24.00 | 13.34 | 26.99 | 17.21 | 35.75 | 51.85 | 47.96 | 83.73 |
Crinetics Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Crinetics Pharmaceuticals, Inc. (CRNX) has a return on equity (ROE) of -40.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Crinetics Pharmaceuticals, Inc. (CRNX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Crinetics Pharmaceuticals, Inc. (CRNX) has a book value per share of $10.55, based on its most recent annual SEC filing.